EQS-News

H&R GmbH & Co. KGaA: Final Nine-months 2022 once again on a high level

EQS-News: H&R GmbH & Co. KGaA / Key word(s): Quarterly / Interim Statement/Quarter Results H&R GmbH & Co. KGaA: Final Nine-months 2022 once again on a high level 15.11.2022 / 11:11 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release

H&R GmbH & Co. KGaA: Quarterly Report for third quarter of 2022

• Operating result (EBITDA) with € 103.3 million again at very good level
• Full-year result expected at up to € 120.0 million

Salzbergen, Germany, November 15, 2022. H&R GmbH & Co. KGaA (short: H&R KGaA; ISIN DE000A2E4T77) has confirmed its preliminary sales and earnings figures for the third quarter of 2022: From July to September 2022, the company achieved an operating result (EBITDA - consolidated earnings before income taxes, other financial income and expenses as well as amortization, depreciation and impairment losses and write-ups on intangible assets and property, plant and equipment) of EUR 30.5 million (same period of the previous year: EUR 36.8 million). After a moderate start to the year and a very good performance in the middle, the third quarter delivered the second highest contribution to earnings this year. EBIT closed at EUR 17.2 million, down from last year's EUR 24.1 million. Earnings before taxes (EBT) for Q3-2022 were EUR 15.3 million (Q3-2021: EUR 22.6 million), and the company closed at EUR 10.4 million for consolidated net income attributable to shareholders (Q3-2021: EUR 16.0 million). Sales in the third quarter of the current fiscal year increased to EUR 418.7 million (Q3-2021: EUR 319.7 million), mainly due to higher raw material costs compared to the previous year.

Overview of key figures:

in million EUR	Nine months 2022	Nine Months 2021	Diff. abs.
Sales Revenues	1,224.5	878.2	346.3
ChemPharm REFINING	802.7	556.2	246.5
ChemPharm SALES	401.8	299.2	102.6
PLASTICS	3.2	32.4	1.8
Consolidation	-14.2	-9.6	-4.6
Operative Earnings (EBITDA)	103.3	113.3	-8.0
ChemPharm REFINING	74.3	89.8	-15.5
ChemPharm SALES	29.6	21.8	7.8
PLASTICS	2.4	2.3	0.1
Consolidation	-3.1	-2.6	-0.5
EBIT	63.4	73.2	-9.8
Earnings before Taxes	58.2	67.0	-8.8
Net Income attributable to Shareholders	40.1	47.0	-6.9
Earnings per Share (in EUR)	1.08	1.26	-0.18
Operative Cashflow	-9.0	13.1	-22.1
Free Cashflow	-60.3	-25.5	-34.8
	Q3 2022	Q3 2021	Diff. abs.
Sales Revenues	418.7	319.7	99.0
ChemPharm REFINING	268.4	204.2	64.2
ChemPharm SALES	141.9	108.6	33.3
PLASTICS	13.1	10.9	2.2
Consolidation	-4.7	-3.9	-0.8
Operative Earnings (EBITDA)	30.5	36.8	-6.3
ChemPharm REFINING	19.4	30.9	-11.5
ChemPharm SALES	10.9	6.6	4.3
PLASTICS	1.1	0.5	0.6
Consolidation	-0.9	-1.2	0.3
EBIT	17.2	24.1	-6.9
Earnings before Taxes	15.3	22.6	-7.3
Net Income attributable to Shareholders	10.4	16.0	-5.6
Earnings per Share (in EUR)	0.28	0.43	-0.15
Operative Cashflow	-7.6	12.0	-19.6
Free Cashflow	-31.6	-1.1	30.5
	30/09/2022	31/12/2021	Diff. abs.
Balance Sheet Total	1,003.2	874.4	128.8
Equity	482.1	408.5	73.6
Equity Ratio (in %, difference in percentage points)	48.1	46.7	1.4

Following the increase in its guidance two weeks ago, the company currently continues to expect to achieve the target of up to EUR 120.0 million.